For example, developing monoclonal antibodies or small molecule inhibitors against specific interleukins (e.g., IL-1β, IL-6, IL-17) could effectively inhibit pro-inflammatory cytokine activity and subsequently mitigate the severity of GVHD. The gene discussed is IL17A; the disease is graft versus host disease.